Neuren Pharmaceuticals Limited
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Neuren Pharmaceuticals Limited
Heading into the J.P. Morgan Healthcare conference, pharmas have been focusing on discovery alliances. J&J’s deals look into novel tissue-targeted drugs, ionic liquid delivery technology and cancer vaccine R&D. Lilly teams with Entos on novel methods for delivering neurology drugs.
Janssen Biotech adds to its bispecific antibody pipeline for cancer via pair of collaborations. Ipsen and Accent pair up to investigate new target for acute myeloid leukemia.
IPO Edition: Caribou, AbSci and HCW launched initial public offerings, but three firms that were expected to go public during the week of 19-23 July did not, raising the question of whether investors are beginning to pull back from biopharma offerings.
Public Company Edition: Three $100m-plus US initial public offerings launched on 15 July after two smaller biopharma IPOs earlier in the month. Also, Gelesis announced a SPAC merger, Brii and Amniotics launched ex-US IPOs, and Intellia, Cerevel and Kymera priced large follow-on offerings.
- Large Molecule
- Other Names / Subsidiaries
- Hamilton Pharmaceuticals